Hymexazol-containing composition with excellent bactericidal effect and preparation method of hymexazol-containing composition

Abstract

The invention discloses a hymexazol-containing composition with an excellent sterilization effect and a preparation method, and relates to the technical field of agricultural bactericides, the composition comprises the following raw materials: modified graphene oxide loaded hymexazol, modified graphene oxide loaded metalaxyl, beta-oligomeric acid and a surfactant; the mass ratio of the modified graphene oxide loaded hymexazol to the modified graphene oxide loaded metalaxyl to the beta-oligomeric acid to the surfactant is (3-5): (1.5-2.5): (1-1.5): (0.8-1.2). The hymexazol composition provided by the invention has the advantages of excellent bactericidal effect, high utilization rate and small damage to the environment.

Description

Technical Field

[0001] The present application relates to the field of agricultural fungicide technology, and in particular to a composition containing oxazolidinone with excellent fungicidal effect and a preparation method thereof. Background Art

[0002] Chemical pesticides refer to chemical preparations used in agriculture to prevent pests, diseases and weeds and regulate crop growth. Chemical pesticides have the advantages of fast effect, broad spectrum and good prevention and control effect. Especially when diseases break out, chemical pesticides are often the fastest and most effective measures.

[0003] As a heterocyclic high-efficiency systemic fungicide, oxazolidinone has shown remarkable efficacy in the agricultural field, especially for the prevention and treatment of soil-borne diseases. Its role as a soil disinfectant is indispensable. It can not only effectively control diseases, but also actively promote the growth and development of crop roots, specifically by increasing the number of roots, improving the overall quality of seedlings, and thus enhancing the plant's stress resistance and survival rate. Therefore, oxazolidinone is widely used in multiple links such as seed soaking, foliar spraying, and soil treatment, which is of great significance to improving crop yield and quality.

[0004] However, the application of oxadiazon is not without limitations. Its main drawback is the relative instability of its chemical properties, which is specifically manifested in the excessively fast release rate, which shortens the effective period of the active ingredient in the environment and makes it difficult to maintain the ideal bactericidal effect for a long time. In addition, oxadiazon has poor acid and alkali resistance and UV stability, and is easily degraded in environmental changes, which not only further shortens its effective action time, but also limits its scope of application under different environmental conditions. More seriously, these deficiencies in chemical properties may also lead to the problem of oxadiazon residues in the environment, posing a potential threat to soil, water sources and ecosystems, affecting environmental safety, and increasing the risk of environmental pollution.

[0005] Therefore, how to improve the bactericidal effect of the fungicide composition containing oxazolidinone and reduce the toxic effect is a problem that needs to be solved urgently. Summary of the invention

[0006] In order to improve the fungicidal effect of a composition containing oxazolidinone and increase the effective utilization rate of pesticides, the present application provides a composition containing oxazolidinone with excellent fungicidal effect and a preparation method.

[0007] The composition containing oxazolidinone with excellent bactericidal effect provided in the present application adopts the following technical scheme: A composition containing oxamexazole with excellent bactericidal effect, wherein the raw materials of the composition include modified graphene oxide loaded with oxamexazole, modified graphene oxide loaded with metalaxyl, β-oligomeric acid, and surfactant; the mass ratio of the modified graphene oxide loaded with oxamexazole, the modified graphene oxide loaded with metalaxyl, β-oligomeric acid, and surfactant is 3-5:1.5-2.5:1-1.5:0.8-1.2.

[0008] Preferably, the mass ratio of the modified graphene oxide loaded with oxazolidinone, the modified graphene oxide loaded with metalaxyl, the β-oligomeric acid, and the surfactant is 4:2:1.3:1.

[0009] Preferably, the surfactant is NSF.

[0010] Preferably, the modified graphene oxide loaded with oxadiazine is made from the following raw materials in parts by weight: 0.1-0.2 parts of oxadiazine, 0.2-0.6 parts of dopamine-modified graphene oxide, 3-5 parts of dichloromethane, 3-5 parts of emulsifier, 120-220 parts of water, and 30-60 parts of 7.4% copper sulfate solution.

[0011] Preferably, the modified graphene oxide loaded with metalaxyl is made from the following raw materials in parts by weight: 0.1-0.2 parts of metalaxyl, 0.1-0.3 parts of dopamine-modified graphene oxide, 2-4 parts of dichloromethane, 2-4 parts of emulsifier, 100-200 parts of water, and 27-54 parts of 7.4% copper sulfate solution.

[0012] Preferably, the dopamine-modified graphene oxide is made from the following raw materials in parts by weight: 0.2-0.4 parts of graphene oxide, 200-400 parts of deionized water, 0.03-0.06 parts of tris(hydroxymethyl)aminomethane hydrochloride, and 0.4-0.8 parts of dopamine hydrochloride.

[0013] Preferably, the method for preparing dopamine-modified graphene oxide comprises the following steps: Add graphene oxide to deionized water, disperse it ultrasonically, add tris(hydroxymethyl)aminomethane hydrochloride), stir evenly, add dopamine hydrochloride, stir in a water bath at 60-70° C., polymerize for 24-30 hours, filter, centrifuge, wash, and dry in a vacuum drying oven at 60-70° C. for 24-30 hours to obtain dopamine-modified graphene oxide.

[0014] Preferably, the preparation method of the modified graphene oxide loaded with oxazolidinone comprises the following steps: Dichloromethane, an emulsifier and water are mixed evenly to obtain a mixed solution, oxadiazon is added to the mixed solution and dispersed evenly, dopamine-modified graphene oxide is added and mixed, and the mixture is stirred in the dark for 24-30 hours; the generated product is washed and freeze-dried, and then added to a copper sulfate solution with a mass fraction of 7.4% and dispersed evenly to obtain a suspension, and the suspension is magnetically stirred at room temperature for 12-15 hours, centrifuged, washed, and freeze-dried for standby use to obtain modified graphene oxide loaded with oxadiazon.

[0015] Preferably, the method for preparing the modified graphene oxide loaded with metalaxyl comprises the following steps: Dichloromethane, an emulsifier and water are mixed evenly to obtain a mixed solution, metalaxyl is added to the mixed solution and dispersed evenly, dopamine-modified graphene oxide is added and mixed, and the mixture is stirred in the dark for 24-30 hours; the generated product is washed and freeze-dried, and then added to a copper sulfate solution with a mass fraction of 7.4% and dispersed evenly to obtain a suspension, and the suspension is magnetically stirred at room temperature for 12-15 hours, centrifuged, washed, and freeze-dried for standby use to obtain modified graphene oxide loaded with metalaxyl.

[0016] The present application also provides a method for preparing a composition containing oxazolidinone with excellent bactericidal effect, which adopts the following technical scheme: A method for preparing a composition containing oxazolidinone with excellent bactericidal effect comprises the following steps: The modified graphene oxide loaded with oxadipamide, the modified graphene oxide loaded with metalaxyl, β-oligomeric acid and a surfactant are mixed and stirred evenly to obtain a composition containing oxadipamide.

[0017] In summary, the present application includes at least one of the following beneficial technical effects: 1. By adopting the above technical scheme, metalaxyl is a highly efficient systemic fungicide, which can be absorbed by the roots, stems and leaves of plants and transported to various parts of the plant body with water. It has low toxicity, low residue and long-lasting efficacy. The combination of metalaxyl and oxazolidinone can play a synergistic role, improve the fungicidal activity, and produce prevention and control effects on more types of soil-borne diseases, including damping-off, damping-off, wilt, root rot, etc., effectively improving the fungicidal effect. β-oligomeric acid, as an inducer, can enhance the stress resistance of crops, including resistance to low temperature, salt and drought, and improve the yield and quality of crops. The chelating and stabilizing effect of β-oligomeric acid can also promote the absorption and utilization of trace elements by plants, thereby effectively improving the utilization rate of metalaxyl and oxazolidinone in crops, thereby enhancing the fungicidal effect. 2. Graphene oxide has the advantages of large specific surface area, good water dispersibility, certain antibacterial activity, etc. It is often used as a carrier to construct drug delivery systems. The present application uses polydopamine and copper to modify the surface of graphene oxide, which further increases the interaction between the carrier and the pesticide molecules and has excellent adsorption and loading capacity; polydopamine modification can improve the photostability of graphene oxide-loaded pesticides, so that the pesticides can be slowly released in the natural environment, thereby greatly extending the efficacy period, significantly reducing the frequency of application and the amount of pesticides used, and reducing environmental pollution; copper plays an important role in the integrated management of pests and diseases, and can control fungal oomycetes and bacterial diseases in agriculture; fixing copper ions on polydopamine-modified graphene oxide can effectively control and regulate the release of pesticides, and also has the function of protecting crops. DETAILED DESCRIPTION

[0018] The present application is further described in detail below with reference to the embodiments.

[0019] The chemical reagents used in the preparation examples, embodiments and comparative examples provided by the present invention are all commercially available products, and their brands and manufacturers are as follows: Graphene oxide, Anhui Kerun Nanotechnology Co., Ltd.; Tris(hydroxymethyl)aminomethane hydrochloride, Wuhan Difu Biotechnology Co., Ltd.; Dopamine hydrochloride, Beijing Chemical (Shandong) Co., Ltd.; NSF, Shanghai Beino Biotechnology Co., Ltd.; Methadone, Hubei Zhengxingyuan Fine Chemical Co., Ltd.; Metalaxyl, Sichuan Cullinan Technology Co., Ltd.; Tween-20, Shanghai Aladdin Biochemical Technology Co., Ltd.; Preparation example: Preparation Example 1, 0.2g of graphene oxide is added to 200g of deionized water, ultrasonically dispersed at 21kHz for 60min, 0.03g of tris(hydroxymethyl)aminomethane hydrochloride is added, stirred evenly, 0.4g of dopamine hydrochloride is added, and stirred in a water bath at 60°C. After the polymerization reaction for 24h, the mixture is filtered, centrifuged, and repeatedly rinsed with anhydrous ethanol and deionized water until the supernatant is clarified, and then dried in a vacuum drying oven at 60°C for 24h to obtain dopamine-modified graphene oxide.

[0020] Preparation Example 2, 0.3g of graphene oxide was added to 300g of deionized water, ultrasonically dispersed at 21.5kHz for 70min, 0.045g of tris(hydroxymethyl)aminomethane hydrochloride was added, and stirred evenly, and then 0.6g of dopamine hydrochloride was added. The mixture was stirred in a water bath at 65°C, and the polymerization reaction was carried out for 27h. The mixture was filtered, centrifuged, and repeatedly rinsed with anhydrous ethanol and deionized water until the supernatant was clarified, and then dried in a vacuum drying oven at 65°C for 27h to obtain dopamine-modified graphene oxide.

[0021] Preparation Example 3, 0.4 g of graphene oxide was added to 400 g of deionized water, ultrasonically dispersed at 22 kHz for 80 min, 0.06 g of tris(hydroxymethyl)aminomethane hydrochloride was added, and stirred evenly. Then, 0.8 g of dopamine hydrochloride was added, and stirred in a water bath at 70°C. After the polymerization reaction for 30 h, the mixture was filtered, centrifuged, and repeatedly rinsed with anhydrous ethanol and deionized water until the supernatant was clarified, and then dried in a vacuum drying oven at 70°C for 30 h to obtain dopamine-modified graphene oxide.

[0022] Embodiment: Embodiment 1, S1. 3g of dichloromethane, 3g of emulsifier Tween-20, and 120g of water were mixed to obtain a mixed solution, 0.1g of oxadiazon was added to the mixed solution and dispersed evenly, and then 0.2g of dopamine-modified graphene oxide prepared in Preparation Example 1 was added and mixed, and the mixture was stirred in the dark for 24h; the generated product was washed with deionized water, freeze-dried, added to 30g of copper sulfate solution with a mass fraction of 7.4%, and dispersed evenly to obtain a suspension, and the suspension was magnetically stirred at room temperature for 12h, centrifuged, washed with deionized water, and freeze-dried for standby use to obtain modified graphene oxide loaded with oxadiazon; S2. 2 g of dichloromethane, 2 g of emulsifier Tween-20, and 100 g of water were mixed to obtain a mixed solution, 0.1 g of metalaxyl was added to the mixed solution and dispersed evenly, and then 0.1 g of dopamine-modified graphene oxide prepared in Preparation Example 1 was added and mixed, and the mixture was stirred in the dark for 24 h; the resulting product was washed with deionized water, freeze-dried, added to 27 g of a copper sulfate solution with a mass fraction of 7.4%, and dispersed evenly to obtain a suspension, and the suspension was magnetically stirred at room temperature for 12 h, centrifuged, washed with deionized water, and freeze-dried for standby use to obtain modified graphene oxide loaded with metalaxyl; S3. 3 g of modified graphene oxide loaded with oxadiazon prepared by S1, 1.5 g of modified graphene oxide loaded with metalaxyl prepared by S2, 1 g of β-oligomeric acid, and 0.8 g of surfactant NSF were mixed and stirred uniformly to obtain a composition containing oxadiazon.

[0023] Example 2, S1. 3 g of dichloromethane, 3 g of emulsifier Tween-20, and 120 g of water were mixed to obtain a mixed solution, 0.1 g of oxadipate was added to the mixed solution and dispersed evenly, and then 0.2 g of dopamine-modified graphene oxide prepared in Preparation Example 1 was added and mixed, and the mixture was stirred in the dark for 24 h; the resulting product was washed with deionized water, freeze-dried, added to 30 g of a copper sulfate solution with a mass fraction of 7.4%, and dispersed evenly to obtain a suspension, and the suspension was magnetically stirred at room temperature for 12 h, centrifuged, washed with deionized water, and freeze-dried for standby use to obtain modified graphene oxide loaded with oxadipate; S2. 2 g of dichloromethane, 2 g of emulsifier Tween-20, and 100 g of water were mixed to obtain a mixed solution, 0.1 g of metalaxyl was added to the mixed solution and dispersed evenly, and then 0.1 g of dopamine-modified graphene oxide prepared in Preparation Example 1 was added and mixed, and the mixture was stirred in the dark for 24 h; the resulting product was washed with deionized water, freeze-dried, added to 27 g of a copper sulfate solution with a mass fraction of 7.4%, and dispersed evenly to obtain a suspension, and the suspension was magnetically stirred at room temperature for 12 h, centrifuged, washed with deionized water, and freeze-dried for standby use to obtain modified graphene oxide loaded with metalaxyl; S3. 4 g of modified graphene oxide loaded with oxadiazon prepared by S1, 2 g of modified graphene oxide loaded with metalaxyl prepared by S2, 1.3 g of β-oligomeric acid, and 1 g of surfactant NSF were mixed and stirred uniformly to obtain a composition containing oxadiazon.

[0024] Example 3, S1. 3 g of dichloromethane, 3 g of emulsifier Tween-20, and 120 g of water were mixed to obtain a mixed solution, 0.1 g of oxadipate was added to the mixed solution and dispersed evenly, and then 0.2 g of dopamine-modified graphene oxide prepared in Preparation Example 1 was added and mixed, and the mixture was stirred in the dark for 24 h; the resulting product was washed with deionized water, freeze-dried, added to 30 g of a copper sulfate solution with a mass fraction of 7.4%, and dispersed evenly to obtain a suspension, and the suspension was magnetically stirred at room temperature for 12 h, centrifuged, washed with deionized water, and freeze-dried for standby use to obtain modified graphene oxide loaded with oxadipate; S2. 2 g of dichloromethane, 2 g of emulsifier Tween-20, and 100 g of water were mixed to obtain a mixed solution, 0.1 g of metalaxyl was added to the mixed solution and dispersed evenly, and then 0.1 g of dopamine-modified graphene oxide prepared in Preparation Example 1 was added and mixed, and the mixture was stirred in the dark for 24 h; the resulting product was washed with deionized water, freeze-dried, added to 27 g of a copper sulfate solution with a mass fraction of 7.4%, and dispersed evenly to obtain a suspension, and the suspension was magnetically stirred at room temperature for 12 h, centrifuged, washed with deionized water, and freeze-dried for standby use to obtain modified graphene oxide loaded with metalaxyl; S3. 5 g of modified graphene oxide loaded with oxadiazon prepared by S1, 2.5 g of modified graphene oxide loaded with metalaxyl prepared by S2, 1.5 g of β-oligomeric acid, and 1.2 g of surfactant NSF were mixed and stirred uniformly to obtain a composition containing oxadiazon.

[0025] Example 4, S1. 4 g of dichloromethane, 4 g of emulsifier Tween-20, and 170 g of water were mixed to obtain a mixed solution, 0.15 g of oxadipate was added to the mixed solution and dispersed evenly, and then 0.4 g of dopamine-modified graphene oxide prepared in Preparation Example 1 was added and mixed, and the mixture was stirred in the dark for 27 h; the resulting product was washed with deionized water, freeze-dried, added to 45 g of a copper sulfate solution with a mass fraction of 7.4%, and dispersed evenly to obtain a suspension, and the suspension was magnetically stirred at room temperature for 13.5 h, centrifuged, washed with deionized water, and freeze-dried for standby use to obtain modified graphene oxide loaded with oxadipate; S2. 3 g of dichloromethane, 3 g of emulsifier Tween-20, and 150 g of water were mixed to obtain a mixed solution, 0.15 g of metalaxyl was added to the mixed solution and dispersed evenly, and then 0.2 g of dopamine-modified graphene oxide prepared in Preparation Example 1 was added and mixed, and the mixture was stirred in the dark for 27 h; the resulting product was washed with deionized water, freeze-dried, added to 40 g of a copper sulfate solution with a mass fraction of 7.4%, and dispersed evenly to obtain a suspension, and the suspension was magnetically stirred at room temperature for 13.5 h, centrifuged, washed with deionized water, and freeze-dried for standby use to obtain modified graphene oxide loaded with metalaxyl; S3. 3 g of modified graphene oxide loaded with oxadiazon prepared by S1, 1.5 g of modified graphene oxide loaded with metalaxyl prepared by S2, 1 g of β-oligomeric acid, and 0.8 g of surfactant NSF were mixed and stirred uniformly to obtain a composition containing oxadiazon.

[0026] Example 5, S1. 5 g of dichloromethane, 5 g of emulsifier Tween-20, and 220 g of water were mixed to obtain a mixed solution, 0.2 g of oxadipate was added to the mixed solution and dispersed evenly, and then 0.6 g of dopamine-modified graphene oxide prepared in Preparation Example 1 was added and mixed, and the mixture was stirred in the dark for 30 h; the resulting product was washed with deionized water, freeze-dried, added to 60 g of a copper sulfate solution with a mass fraction of 7.4%, and dispersed evenly to obtain a suspension, and the suspension was magnetically stirred at room temperature for 15 h, centrifuged, washed with deionized water, and freeze-dried for standby use to obtain modified graphene oxide loaded with oxadipate; S2. 4 g of dichloromethane, 4 g of emulsifier Tween-20, and 200 g of water were mixed to obtain a mixed solution, 0.2 g of metalaxyl was added to the mixed solution and dispersed evenly, and then 0.3 g of dopamine-modified graphene oxide prepared in Preparation Example 1 was added and mixed, and the mixture was stirred in the dark for 30 h; the resulting product was washed with deionized water, freeze-dried, added to 54 g of a copper sulfate solution with a mass fraction of 7.4%, and dispersed evenly to obtain a suspension, and the suspension was magnetically stirred at room temperature for 15 h, centrifuged, washed with deionized water, and freeze-dried for standby use to obtain modified graphene oxide loaded with metalaxyl; S3. 3 g of modified graphene oxide loaded with oxadiazon prepared by S1, 1.5 g of modified graphene oxide loaded with metalaxyl prepared by S2, 1 g of β-oligomeric acid, and 0.8 g of surfactant NSF were mixed and stirred uniformly to obtain a composition containing oxadiazon.

[0027] Example 6: The difference between Example 6 and Example 1 is that Example 6 uses dopamine-modified graphene oxide ion Preparation Example 2.

[0028] Example 7: The difference between Example 7 and Example 1 is that the dopamine-modified graphene oxide ion preparation example 3 is used in Example 7.

[0029] Comparative Example: Comparative Example 1, S1. 3 g of dichloromethane, 3 g of emulsifier Tween-20, and 120 g of water were mixed to obtain a mixed solution, 0.1 g of oxadipate was added to the mixed solution and dispersed evenly, and then 0.2 g of dopamine-modified graphene oxide prepared in Preparation Example 1 was added and mixed, and the mixture was stirred in the dark for 24 h; the resulting product was washed with deionized water, freeze-dried, added to 30 g of a copper sulfate solution with a mass fraction of 7.4%, and dispersed evenly to obtain a suspension, and the suspension was magnetically stirred at room temperature for 12 h, centrifuged, washed with deionized water, and freeze-dried for standby use to obtain modified graphene oxide loaded with oxadipate; S2. 2 g of dichloromethane, 2 g of emulsifier Tween-20, and 100 g of water were mixed to obtain a mixed solution, 0.1 g of metalaxyl was added to the mixed solution and dispersed evenly, and then 0.1 g of dopamine-modified graphene oxide prepared in Preparation Example 1 was added and mixed, and the mixture was stirred in the dark for 24 h; the resulting product was washed with deionized water, freeze-dried, added to 27 g of a copper sulfate solution with a mass fraction of 7.4%, and dispersed evenly to obtain a suspension, and the suspension was magnetically stirred at room temperature for 12 h, centrifuged, washed with deionized water, and freeze-dried for standby use to obtain modified graphene oxide loaded with metalaxyl; S3. 2 g of modified graphene oxide loaded with oxadiazon prepared by S1, 1 g of modified graphene oxide loaded with metalaxyl prepared by S2, 0.5 g of β-oligomeric acid, and 0.4 g of surfactant NSF were mixed and stirred uniformly to obtain a composition containing oxadiazon.

[0030] Comparative Example 2, S1. 3 g of dichloromethane, 3 g of emulsifier Tween-20, and 120 g of water were mixed to obtain a mixed solution, 0.1 g of oxadipate was added to the mixed solution and dispersed evenly, and then 0.2 g of dopamine-modified graphene oxide prepared in Preparation Example 1 was added and mixed, and the mixture was stirred in the dark for 24 h; the resulting product was washed with deionized water, freeze-dried, added to 30 g of a copper sulfate solution with a mass fraction of 7.4%, and dispersed evenly to obtain a suspension, and the suspension was magnetically stirred at room temperature for 12 h, centrifuged, washed with deionized water, and freeze-dried for standby use to obtain modified graphene oxide loaded with oxadipate; S2. 2 g of dichloromethane, 2 g of emulsifier Tween-20, and 100 g of water were mixed to obtain a mixed solution, 0.1 g of metalaxyl was added to the mixed solution and dispersed evenly, and then 0.1 g of dopamine-modified graphene oxide prepared in Preparation Example 1 was added and mixed, and the mixture was stirred in the dark for 24 h; the resulting product was washed with deionized water, freeze-dried, added to 27 g of a copper sulfate solution with a mass fraction of 7.4%, and dispersed evenly to obtain a suspension, and the suspension was magnetically stirred at room temperature for 12 h, centrifuged, washed with deionized water, and freeze-dried for standby use to obtain modified graphene oxide loaded with metalaxyl; S3. 6 g of modified graphene oxide loaded with oxadiazon prepared by S1, 3 g of modified graphene oxide loaded with metalaxyl prepared by S2, 2 g of β-oligomeric acid, and 1.6 g of surfactant NSF were mixed and stirred uniformly to obtain a composition containing oxadiazon.

[0031] Comparative Example 3: The difference between Comparative Example 3 and Example 1 is that the oxazolidinone and metalaxyl used in Comparative Example 3 are not treated with modified graphene oxide loading.

[0032] Comparative Example 4: The difference between Comparative Example 4 and Example 1 is that no β-oligomeric acid is added in Comparative Example 4.

[0033] Comparative Example 5: The difference between Comparative Example 5 and Example 1 is that the surfactant NSF is not added in Comparative Example 5.

[0034] Comparative Example 6: The difference between Comparative Example 6 and Example 1 is that the graphene oxide used in Comparative Example 6 is not modified with dopamine, and the preparation method is as follows: S1. 3 g of dichloromethane, 3 g of emulsifier Tween-20, and 120 g of water were mixed to obtain a mixed solution, 0.1 g of oxadipate was added to the mixed solution and dispersed evenly, and 0.2 g of graphene oxide was added and mixed, and the mixture was stirred in the dark for 24 h; the resulting product was washed with deionized water, freeze-dried, added to 30 g of a copper sulfate solution with a mass fraction of 7.4%, and dispersed evenly to obtain a suspension, and the suspension was magnetically stirred at room temperature for 12 h, centrifuged, washed with deionized water, and freeze-dried for standby use to obtain graphene oxide loaded with oxadipate; S2. 2 g of dichloromethane, 2 g of emulsifier Tween-20, and 100 g of water were mixed to obtain a mixed solution, 0.1 g of metalaxyl was added to the mixed solution and dispersed evenly, and then 0.1 g of graphene oxide was added and mixed, and the mixture was stirred in the dark for 24 h; the resulting product was washed with deionized water, freeze-dried, added to 27 g of a copper sulfate solution with a mass fraction of 7.4%, and dispersed evenly to obtain a suspension, and the suspension was magnetically stirred at room temperature for 12 h, centrifuged, washed with deionized water, and freeze-dried for standby use to obtain graphene oxide loaded with metalaxyl; S3. 3 g of graphene oxide loaded with oxadiazon prepared in S1, 1.5 g of graphene oxide loaded with metalaxyl prepared in S2, 1 g of β-oligomeric acid, and 0.8 g of surfactant NSF were mixed and stirred uniformly to obtain a composition containing oxadiazon.

[0035] Comparative Example 7: The difference between Comparative Example 7 and Example 1 is that the modified graphene oxide loaded with oxazolidinone used in Comparative Example 7 is not treated with a copper sulfate solution, and the preparation method is as follows: S1. 3 g of dichloromethane, 3 g of emulsifier Tween-20, and 120 g of water were mixed to obtain a mixed solution, 0.1 g of oxadipate was added to the mixed solution and dispersed evenly, and then 0.2 g of dopamine-modified graphene oxide prepared in Preparation Example 1 was added and mixed, and the mixture was stirred in the dark for 24 h; the resulting product was washed with deionized water and freeze-dried to obtain modified graphene oxide loaded with oxadipate; S2. 2 g of dichloromethane, 2 g of emulsifier Tween-20, and 100 g of water were mixed to obtain a mixed solution, 0.1 g of metalaxyl was added to the mixed solution and dispersed evenly, and then 0.1 g of dopamine-modified graphene oxide prepared in Preparation Example 1 was added and mixed, and the mixture was stirred in the dark for 24 h; the resulting product was washed with deionized water and freeze-dried to obtain modified graphene oxide loaded with metalaxyl; S3. 3 g of modified graphene oxide loaded with oxadiazon prepared by S1, 1.5 g of modified graphene oxide loaded with metalaxyl prepared by S2, 1 g of β-oligomeric acid, and 0.8 g of surfactant NSF were mixed and stirred uniformly to obtain a composition containing oxadiazon.

[0036] Performance testing: The efficacy test of the composition containing oxazolidinone for preventing and controlling turfgrass wilt disease: Examples 1-7, Comparative Examples 1-7 and a group of blank controls, a total of 14 treatment groups, each treatment group was repeated 3 times, and 60 kg of water per mu was added for uniform spraying during the growth period after lawn planting (about 20-25 days after planting). The wilt disease index of each treatment was investigated 14 days after the application of the drug, and the relative control effect was calculated based on the disease index of the control area. The investigation results are shown in Table 1.

[0037] The specific test results are as follows:

[0038] It can be seen from the test results in Table 1 that the composition containing oxazolidinone provided in the present application has a good control effect on turfgrass wilt disease.

[0039] This specific embodiment is merely an explanation of the present application and is not a limitation of the present application. After reading this specification, those skilled in the art may make modifications to the present embodiment without any creative contribution as needed, but such modifications are protected by the patent law as long as they are within the scope of the claims of the present application.

Claims

1. A composition containing oxazolidinone having excellent bactericidal effect, characterized in that: The raw materials of the composition include modified graphene oxide loaded with oxamexazole, modified graphene oxide loaded with metalaxyl, β-oligomeric acid, and surfactant; the mass ratio of the modified graphene oxide loaded with oxamexazole, modified graphene oxide loaded with metalaxyl, β-oligomeric acid, and surfactant is 3-5:1.5-2.5:1-1.5:0.8-1.

2.

2. The composition containing oxazolidinone having excellent bactericidal effect according to claim 1, characterized in that: The mass ratio of the modified graphene oxide loaded with oxazolidinone, the modified graphene oxide loaded with metalaxyl, the β-oligomeric acid, and the surfactant is 4:2:1.3:

1.

3. The composition containing oxazolidinone having excellent bactericidal effect according to claim 1 or 2, characterized in that: The surfactant is NSF.

4. The composition containing oxazolidinone having excellent bactericidal effect according to claim 1, characterized in that: The modified graphene oxide loaded with oxadiazine is prepared from the following raw materials in parts by weight: 0.1-0.2 parts of oxadiazine, 0.2-0.6 parts of dopamine-modified graphene oxide, 3-5 parts of dichloromethane, 3-5 parts of emulsifier, 120-220 parts of water, and 30-60 parts of copper sulfate solution with a mass fraction of 7.4%.

5. The composition containing oxazolidinone having excellent bactericidal effect according to claim 1, characterized in that: The modified graphene oxide loaded with metalaxyl is prepared from the following raw materials in parts by weight: 0.1-0.2 parts of metalaxyl, 0.1-0.3 parts of dopamine-modified graphene oxide, 2-4 parts of dichloromethane, 2-4 parts of emulsifier, 100-200 parts of water, and 27-54 parts of copper sulfate solution with a mass fraction of 7.4%.

6. The composition containing oxazolidinone having excellent bactericidal effect according to claim 4 or 5, characterized in that: The dopamine-modified graphene oxide is prepared from the following raw materials in parts by weight: 0.2-0.4 parts of graphene oxide, 200-400 parts of deionized water, 0.03-0.06 parts of tris(hydroxymethyl)aminomethane hydrochloride, and 0.4-0.8 parts of dopamine hydrochloride.

7. The composition containing oxazolidinone having excellent bactericidal effect according to claim 6, characterized in that: The preparation method of the dopamine-modified graphene oxide comprises the following steps: Add graphene oxide to deionized water, disperse it ultrasonically, add tris(hydroxymethyl)aminomethane hydrochloride), stir evenly, add dopamine hydrochloride, stir in a water bath at 60-70° C., polymerize for 24-30 hours, filter, centrifuge, wash, and dry in a vacuum drying oven at 60-70° C. for 24-30 hours to obtain dopamine-modified graphene oxide.

8. The composition containing oxazolidinone having excellent bactericidal effect according to claim 4, characterized in that: The preparation method of modified graphene oxide loaded with oxazolidinone comprises the following steps: Dichloromethane, an emulsifier and water are mixed evenly to obtain a mixed solution, oxadiazon is added to the mixed solution and dispersed evenly, dopamine-modified graphene oxide is added and mixed, and the mixture is stirred in the dark for 24-30 hours; the generated product is washed and freeze-dried, and then added to a copper sulfate solution with a mass fraction of 7.4% and dispersed evenly to obtain a suspension, and the suspension is magnetically stirred at room temperature for 12-15 hours, centrifuged, washed, and freeze-dried for standby use to obtain modified graphene oxide loaded with oxadiazon.

9. The composition containing oxazolidinone having excellent bactericidal effect according to claim 1, characterized in that: The preparation method of modified graphene oxide loaded with metalaxyl comprises the following steps: Dichloromethane, an emulsifier and water are mixed evenly to obtain a mixed solution, metalaxyl is added to the mixed solution and dispersed evenly, dopamine-modified graphene oxide is added and mixed, and the mixture is stirred in the dark for 24-30 hours; the generated product is washed and freeze-dried, and then added to a copper sulfate solution with a mass fraction of 7.4% and dispersed evenly to obtain a suspension, and the suspension is magnetically stirred at room temperature for 12-15 hours, centrifuged, washed, and freeze-dried for standby use to obtain modified graphene oxide loaded with metalaxyl.

10. The method for preparing the composition containing oxazolidinone with excellent bactericidal effect according to any one of claims 1 to 9, characterized in that: The following steps are involved: The modified graphene oxide loaded with oxadipamide, the modified graphene oxide loaded with metalaxyl, β-oligomeric acid and a surfactant are mixed and stirred evenly to obtain a composition containing oxadipamide.

Images